US20050054616A1 - Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation - Google Patents

Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation Download PDF

Info

Publication number
US20050054616A1
US20050054616A1 US10/886,099 US88609904A US2005054616A1 US 20050054616 A1 US20050054616 A1 US 20050054616A1 US 88609904 A US88609904 A US 88609904A US 2005054616 A1 US2005054616 A1 US 2005054616A1
Authority
US
United States
Prior art keywords
zoledronate
crystalline solid
zoledronic acid
peaks
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/886,099
Other languages
English (en)
Inventor
Judith Aronhime
Revital Lifshitz-Liron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/886,099 priority Critical patent/US20050054616A1/en
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIFSHITZ-LIRON, REVITAL, ARONHIME, JUDITH
Publication of US20050054616A1 publication Critical patent/US20050054616A1/en
Priority to US11/527,362 priority patent/US20070021619A1/en
Priority to US11/527,258 priority patent/US7582768B2/en
Priority to US11/527,348 priority patent/US7589211B2/en
Priority to US11/527,255 priority patent/US7687636B2/en
Priority to US11/527,083 priority patent/US20070021616A1/en
Priority to US11/527,254 priority patent/US7435827B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the invention relates to polymorphs of zoledronic acid and zoledronate sodium salts, amorphous zoledronate sodium salt, processes for making the polymorphs and amorphous zoledronate sodium salt and pharmaceutical compositions containing the polymorphs and amorphous zoledronate sodium salt.
  • Zoledronic acid is a bisphosphonic acid, which is an inhibitor of osteoclastic bone resorption.
  • Zoledronic acid designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid is marketed in the U.S. under the name Zometa® (zoledronic acid for injection).
  • Zometa® is available in vials as a sterile powder for reconstitution for intravenous infuision.
  • the prescribing information for Zometa® states that each vial of Zometa® contains 4.264 mg of zoledronic acid monohydrate (corresponding to 4 mg zoledronic acid on an anhydrous basis).
  • U.S. Pat. No. 4,939,130 discloses a method for making substituted alkanediphosphonic acids.
  • Example 10 describes a method for making zoledronic acid.
  • the product which is recrystallized from water, has a melting point of 239° C. with decomposition.
  • repetition of the procedure described in Example 10 did not lead to zoledronic acid; instead, the starting material was collected at the end of the reaction.
  • the last step of crystallization could not be repeated exactly since the detailed experimental parameters are not given (different cooling regimes, for instance, can produce different polymorphs when crystallized in the same solvent).
  • the solid state physical properties of a compound can be influenced by controlling the conditions under which the compounds are obtained in solid form.
  • Solid state physical properties include, for example, the flowability of the milled solid. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.
  • Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid.
  • the rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream.
  • the rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments.
  • the solid state form of a compound may also affect its behavior on compaction and its storage stability.
  • polymorphic form may give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • a particular polymorphic form may also give rise to distinct spectroscopic properties that may be detectable by powder X-ray diffraction (PXRD), solid state 13 C NMR spectrometry and infrared spectrometry.
  • the discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.
  • the invention provides for new polymorphic forms of zoledronic acid and zoledronate sodium, and for amorphous zoledronate sodium.
  • FIG. 1 is a representative PXRD pattern of zoledronic acid Form I.
  • FIG. 2 is a representative DSC curve of zoledronic acid Form I.
  • FIG. 3 is a representative PXRD pattern of zoledronic acid Form II.
  • FIG. 4 is a representative PXRD pattern of zoledronic acid Form XII.
  • FIG. 5 is a representative PXRD pattern of zoledronic acid Form XV.
  • FIG. 6 is a representative PXRD pattern of zoledronic acid Form XVIII.
  • FIG. 7 is a representative PXRD pattern of zoledronic acid Form XX.
  • FIG. 8 is a representative PXRD pattern of zoledronic acid Form XXVI.
  • FIG. 9 is a representative PXRD pattern of zoledronate monohydrate Form VIII.
  • FIG. 10 is a representative PXRD pattern of zoledronate monosodium Form XVI.
  • FIG. 11 is a representative PXRD pattern of zoledronate monosodium Form XVII.
  • FIG. 12 is a representative PXRD pattern of zoledronate disodium Form V.
  • FIG. 13 is a representative PXRD pattern of zoledronate disodium Form VI.
  • FIG. 14 is a representative PXRD pattern of zoledronate disodium Form VII.
  • FIG. 15 is a representative PXRD pattern of zoledronate disodium Form X.
  • FIG. 16 is a representative PXRD pattern of zoledronate disodium Form XIII.
  • FIG. 17 is a representative PXRD pattern of zoledronate disodium Form XIV.
  • FIG. 18 is a representative PXRD pattern of zoledronate disodium Form XIX.
  • FIG. 19 is a representative PXRD pattern of zoledronate disodium Form XXV.
  • FIG. 20 is a representative PXRD pattern of zoledronate disodium Form XXVII.
  • FIG. 21 is a representative PXRD pattern of zoledronate disodium Form IX.
  • FIG. 22 is a representative PXRD pattern of zoledronate disodium Form XI.
  • FIG. 23 is a representative PXRD pattern of zoledronate sodium amorphous.
  • FIG. 24 is a representative TGA curve of zoledronic acid Form I.
  • FIG. 25 is a representative TGA curve of zoledronic acid Form II.
  • FIG. 26 is a representative TGA curve of zoledronic acid Form XII.
  • FIG. 27 is a representative TGA curve of zoledronic acid Form XV.
  • FIG. 28 is a representative TGA curve of zoledronic acid Form XVIII.
  • FIG. 29 is a representative TGA curve of zoledronic acid Form XX.
  • FIG. 30 is a representative TGA curve of zoledronic acid Form XXVI.
  • FIG. 31 is a representative TGA curve of zoledronate monosodium Form VIII.
  • FIG. 32 is a representative TGA curve of zoledronate monosodium Form XVI.
  • FIG. 33 is a representative TGA curve of zoledronate monosodium Form XVII.
  • FIG. 34 is a representative TGA curve of zoledronate disodium Form V.
  • FIG. 35 is a representative TGA curve of zoledronate disodium Form VI.
  • FIG. 36 is a representative TGA curve of zoledronate disodium Form VII.
  • FIG. 37 is a representative TGA curve of zoledronate disodium Form X.
  • FIG. 38 is a representative TGA curve of zoledronate disodium Form XIII.
  • FIG. 39 is a representative TGA curve of zoledronate disodium Form XIV.
  • FIG. 40 is a representative TGA curve of zoledronate disodium Form XIX.
  • FIG. 41 is a representative TGA curve of zoledronate disodium Form XXV.
  • FIG. 42 is a representative TGA curve of zoledronate disodium Form XXVII.
  • FIG. 43 is a representative TGA curve of zoledronate disodium Form IX.
  • FIG. 44 is a representative TGA curve of zoledronate disodium Form XI.
  • the invention relates to polymorphs of zoledronic acid and zoledronate sodium salts, amorphous zoledronate sodium salt, processes for making the polymorphs and amorphous zoledronate sodium salt and pharmaceutical compositions containing the polymorphs and amorphous zoledronate sodium salt.
  • the invention can be understood by reference to the following numbered embodiments.
  • Crystalline solid zoledronic acid (Form I) characterized by a powder X-ray diffraction pattern having peaks at 12.1, 12.8, 15.7, and 18.9 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronic acid of embodiment 1 further characterized by a powder XRD pattern with peaks at 20.9, 21.3, 21.8, 22.2, 25.8, 27.6, 29.2, 32.5, and 32.9 ⁇ 0.2° 2 ⁇ .
  • a pharmaceutical composition comprising the crystalline zoledronic acid of any of embodiments 1-11.
  • Crystalline solid zoledronic acid (Form II) characterized by a powder X-ray diffraction pattern having peaks at 14.6, 15.4, 19.1, 22.9, and 23.9 ⁇ 0.2° 2 ⁇ .
  • the crystalline zoledronic acid of embodiment 14 further characterized by a powder X-ray diffraction pattern with peaks at 20.8, 21.7, 25.1, 26.7, 29.5, 29.9, and ⁇ 0.2° 2 ⁇ .
  • Crystalline solid zoledronic acid (Form XII) characterized by a powder X-ray pattern having peaks at 9.0, 13.9, 14.8, 21.5, 24.7, and 29.8'0.2° 2 ⁇ .
  • the crystalline zoledronic acid of embodiment 17 further characterized by a powder X-ray diffraction pattern with peaks at 17.0, 20.6, 20.8, 22.4, 25.8, 27.7, 28.4, 28.7, 29.1, 30.8, 3.19, 32.3, and 32.9 ⁇ 0.2° 2 ⁇ .
  • Crystalline solid zoledronic acid (Form XV) characterized by a powder X-ray diffraction pattern having peaks at 10.1, 17.3, 19.3, and 23.2 ⁇ 0.2° 2 ⁇ .
  • the crystalline zoledronic acid of embodiment 20 further characterized by a powder X-ray diffraction pattern with peaks at 14.5, 16.7, 18.1, 24.5, 25.1, 25.7, 28.5, 29.1, 29.6, and 30.4 ⁇ 0.2° 2 ⁇ .
  • Crystalline solid zoledronic acid (Form XVIII) characterized by a powder X-ray diffraction pattern having peaks at 10.7, 13.0, 16.4, 17.4, and 28.5 ⁇ 0.2° 2 ⁇ .
  • the crystalline zoledronic acid of embodiment 23 further characterized by a powder X-ray diffraction pattern with peaks at 13.3, 18.1, 19.3, 21.3, 23.7, 25.9, 31.5, and 34.5 ⁇ 0.2° 2 ⁇ .
  • Crystalline solid zoledronic acid (Form XX) characterized by a powder X-ray diffraction pattern having peaks at 12.2, 19.3, 20.2, 21.3, 25.1, and 27.25 ⁇ 0.2° 2 ⁇ .
  • the crystalline zoledronic acid of embodiment 26 further characterized by a powder X-ray diffraction pattern with peaks at 11.4, 14.9, 15.5, 17.2, 18.2 and 30.5 ⁇ 0.2° 2 ⁇ .
  • Crystalline solid zoledronic acid (Form XXVI) characterized by a powder X-ray diffraction pattern having peaks at 9.8, 14.5, 17.1, 17.6, and 18.3 ⁇ 0.2° 2 ⁇ .
  • the crystalline zoledronic acid of embodiment 29 further characterized by a powder X-ray diffraction pattern with peaks at 18.8, 19.7, 21.4, 25.7, 26.6, and 28.1 ⁇ 0.2° 2 ⁇ .
  • a pharmaceutical composition comprising the crystalline solid zoledronic acid of any of embodiments 12-31.
  • the crystalline solid zoledronate monosodium of embodiment 35 further characterized by a powder X-ray diffraction pattern with peaks at 11.8, 17.6, 20.1, 24.7, 25.0, 28.4, 31.7, and 32.8 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate monosodium of embodiment 33 characterized by a powder X-ray diffraction pattern having peaks at 7.3, 8.8, 14.7, 21.8, and 29.6 ⁇ 0.2° 2 ⁇ (form XVI).
  • the crystalline solid zoledronate monosodium of embodiment 38 further characterized by a powder X-ray diffraction pattern with peaks at 13.8, 16.8, 20.4, 21.4, 24.4, 25.6, 27.5, 28.2, and 31.7 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate monosodium of embodiment 41 further characterized by a powder X-ray diffraction pattern with peaks at 13.9, 15.5, 16.8, 18.6, 22.3, 23.6, 26.7, 27.7, and 32.3 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 47 further characterized by a powder X-ray diffraction pattern with peaks at 18.0, 18.9, 19.7, 22.7, 25.0, 26.7, 30.9, and 34.5 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 44 characterized by a powder X-ray diffraction pattern having peaks at 7.2, 13.3, 13.7, 14.5, and 21.7 ⁇ 0.2° 2 ⁇ (Form VI).
  • the crystalline solid zoledronate disodium of embodiment 50 further characterized by a powder X-ray diffraction pattern with peaks at 8.2, 16.6, 16.9, 17.3, 25.9, 26.6, 30.7, 31.9, and 32.9 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 53 further characterized by a powder X-ray diffraction pattern with peaks at 22.0, 23.2, 26.4, 27.1, 28.6, 28.8, 34.2 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 56 further characterized by a powder X-ray diffraction pattern with peaks at 8.8, 13.7, 17.0, 19.8, 21.3, 24.4, 27.5, 27.9, 30.9, and 33.4 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 59 further characterized by a powder X-ray diffraction pattern with peaks at 10.2, 19.0, 20.0, 20.6, 22.3, 27.4, 28.6, 28.9, and 34.8 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 62 further characterized by a powder X-ray diffraction pattern with peaks at 13.0, 15.1, 17.1, 20.5, 27.7, 29.6, 30.7, and 33.5 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 65 further characterized by a powder X-ray diffraction pattern with peaks at 6.2, 14.3, 15.3, 16.0, 18.5, 24.3, and 28.6 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 68 further characterized by a powder X-ray diffraction pattern with peaks at 6.3, 9.5, 12.6, 14.6, 26.2, 27.1, and 28.6 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate disodium of embodiment 44 which is a monohydrate characterized by a powder X-ray diffraction pattern having peaks at 6.4, 8.2, 16.0, 17.4, 19.0, and 28.8 ⁇ 0.2° 2 ⁇ (Form XXVII).
  • the crystalline solid zoledronate disodium of embodiment 71 further characterized by a powder X-ray diffraction pattern with peaks at 7.7, 10.2, 17.2, 18.1, 21.6, 25.7, and 25.9 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate trisodium of embodiment 75 further characterized by a powder X-ray diffraction pattern with peaks at 13.1, 20.2, 20.6, 20.9, 25.0, 27.8, and 29.0 ⁇ 0.2° 2 ⁇ .
  • the crystalline solid zoledronate trisodium of embodiment 78 further characterized by a powder X-ray diffraction pattern with peaks at 15.0, 15.4, 17.5, 18.8, 19.6, 20.5, 22.3, 23.7, 25.7, 29.6, and 31.7 0.2° 2 ⁇ .
  • a process for preparing a solid crystalline zoledronate sodium salt comprising:
  • a process for preparing a crystalline solid zoledronate sodium salt comprising:
  • a process for preparing a solid crystalline zoledronate sodium salt comprising:
  • a process for preparing crystalline solid zoledronate monosodium Form VIII comprising:
  • a process for preparing crystalline solid zoledronate monosodium Form VIII comprising:
  • a process for preparing crystalline solid zoledronate monosodium Form VIII comprising:
  • a process for preparing crystalline solid zoledronate monosodium Form XVI comprising:
  • a process for preparing crystalline solid zoledronate monosodium Form XVI comprising:
  • a process for preparing crystalline solid zoledronate monosodium Form XVI comprising:
  • a process for preparing solid crystalline zoledronate sodium Form XVII comprising:
  • a pharmaceutical composition comprising the crystalline solid zoledronate monosodium of any of embodiments 35-43.
  • a pharmaceutical composition comprising the crystalline solid zoledronate disodium of any of embodiments 47-73.
  • a pharmaceutical composition comprising the crystalline solid zoledronate trisodium of any of embodiments 75-80.
  • a pharmaceutical composition comprising the amorphous solid zoledronate of any of embodiments 126, 127 and 128.
  • a process for preparing zoledronate amorphous sodium comprising: treating zoledronic acid and a base, preferably sodium hydroxide, in water at room temperature and precipitating zoledronate amorphous sodium.
  • Powder X-ray diffraction (“PXRD”) analysis was performed on a Scintag X-Ray powder diffractometer model X'TRA equipped with a solid state detector. Copper radiation of 1.5418 ⁇ was used. A round aluminium sample holder with round zero background quartz plate, with a cavity of 25 mm diameter and 0.5 mm depth, was used.
  • LOD Loss on drying
  • TGA Thermal Gravimetric Analysis
  • DSC analysis was done using a Mettler 821 Star e .
  • the weight of the samples was about 3 mg.
  • the samples were scanned at a rate of 10° C./min from 30° C. to 300° C.
  • the oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min. Standard 40 ml aluminum crucibles covered by lids with three holes were used.
  • Applicants have discovered that different crystal forms of Zoledronic acid may be obtained. Different forms of the zoledronic acid may have improved properties with regards to dissolution (since the dosage form is for injection, the material needs to be reconstituted in water; faster dissolution rate would mean faster reconstitution).
  • the recrystallization of Zoledronic acid leads to a material with a purity of at least 99.5% area by HPLC.
  • the novel forms of zoledronic acid are hydrated.
  • the level of water in Zoledronic acid is estimated by TGA the (thermogravimetric analysis) weight loss.
  • Zoledronic acid can be found in the anhydrous state (weight loss up to 2%), monohydrate (weight loss 5-8%), sesquihydrate (weight loss 9-11%).
  • a typical DSC scan of zoledronic acid shows an endothermic peak below about 160-170° C. due mainly to water desorption, and a subsequent endotherm at about 200° C. concomitant to an exotherm reaction (see FIG. 2 ). From this DSC scan there is no clear detection of a melting point.
  • the invention provides a novel crystalline solid form of Zoledronic acid that has been denominated Form I.
  • Zoledronic acid Form I identified by its PXRD pattern, a representative example of which is provided in the diffractoram of FIG. 1 .
  • Particular characteristic peaks occur at 12.1, 12.8, 15.7, and 18.9 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 20.9, 21.3, 21.8, 22.2, 25.8, 27.6, 29.2, 32.5, and 32.9 ⁇ 0.2° 2 ⁇ .
  • the hydration level of Zoledronic acid Form I is indicated by a LOD of 5% to 8% (monohydrate) on heating from about 25-220° C.
  • Zoledronic acid Form I is substantially free of Zoledronic acid Form II.
  • Zoledronic acid Form I is substantially free of other polymorphic forms of Zoledronic acid. Substantially free means less than about 5%.
  • a suitable method for detecting other phases and mixtures of polymorphs is the X-Ray powder diffraction method (see “Polymorphism in molecular crystals”, Joel Bernstein, Oxford Science Publications, or “Polymorphism in pharmaceutical solids” edited by Harry G. Brittain).
  • Zoledronic acid Form I is physically stable and does not substantially transform to any other crystal form when exposed to 100% relative humidity (RH) or less, for one week, or stored at 40° C. and 75% RH for 3 months. After exposure to 100% RH or less, for one week, there is no significant gain of moisture in Form I (not significant means that it absorbs less than about 0.2% water). “Substantially transforms to any other crystal form” means that more than about 5% of the crystal form converts or rearranges to Form II or any other crystal form.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising zoledronic acid Form I substantially free of other polymorphic forms of zoledronic acid and at least one pharmaceutically acceptable excipient.
  • the pharmaceutical composition is in the form of an oral solid dosage form.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising zoledronic acid Form I, which is physically stable and does not substantially transform to any other crystal form when stored at 40° C. and 75% RH for 3 months, and at least one pharmaceutically acceptable excipient.
  • the pharmaceutical composition is in the form of an oral solid dosage form.
  • novel crystal forms of Zoledronic acid preferably have a particle size distribution such that 100% of the particles have a size below 100 microns, preferably below 50 microns.
  • another aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a novel crystal form of zoledronic acid, which has a particle size distribution such that 100% is below 100 microns, preferably below 50 microns, and at least one pharmaceutically acceptable excipient.
  • Zoledronic acid Form I can be prepared by a phosphorylation reaction of 1-Imidazoleacetic acid (IAA) in the presence of Phosphorous acid and Phosphorous oxychloride in a diluent, such as, Toluene, Chlorobenzene, PEG-400 and Silicon oil.
  • IAA 1-Imidazoleacetic acid
  • Phosphorous oxychloride is added to a mixture of Phosphorous acid and IAA at 75° C.-80° C.
  • the reaction mixture is then stirred at 80° C.-100° C., preferably at 80° C. for 1-34 hours, preferably 5-25 hours.
  • water is added at 80° C.-100° C. and the aqueous phase is separated.
  • Hydrolysis occurs in about 10-20 hrs, preferably 14-16 hours.
  • a solvent like ethanol or acetone may be added to obtain a precipitate of ZLD-Ac after stirring at 5° C. for 1-6 hours, preferably 2.5-4 hours.
  • the invention provides a novel crystalline solid form of Zoledronic acid that has been denominated Form II.
  • Zoledronic acid Form II can be identified by its PXRD pattern, a representative example of which is provided in the diffractogram of FIG. 3 . Particular characteristic peaks occur at 14.6, 15.4, 19.1, 22.9, and 23.9 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 20.8, 21.7, 25.1, 26.7, 29.5, 29.9, and ⁇ 0.2° 2 ⁇ .
  • the hydration level of Zoledronic acid Form II is indicated by a LOD of about 5% (monohydrate) on heating from about 25-220° C.
  • Form II can be prepared by a phosphorylation reaction of 1-Imidazoleacetic acid (IAA, 1 eq.) in the presence of Phosphorous acid (2 eq.) and Phosphorous oxychloride (3.7 eq.) in silicon oil as a diluent.
  • Phosphorous oxychloride is added to a mixture of phosphorous acid and IAA at 75° C.
  • the reaction mixture is then heated to 80° C. for about 27 hours.
  • water is added at 80° C. and the aqueous phase is separated.
  • Hydrolysis usually occurs within about 10-20 hrs, preferably 14-16 hours.
  • ethanol is added to obtain a precipitate of ZLD-Ac after stirring at 5° C. for 1-6 hours, preferably 2.5-4 hours.
  • Zoledronic acid Form II can also be prepared by treating Zoledronic acid form I in Toluene, preferably at reflux temperature, for a duration of 5-20 hours, most preferably 10-16 hours.
  • the invention provides a novel crystalline solid form of Zoledronic acid that has been denominated Form XII.
  • Zoledronic acid Form XII can be idenfitied by its PXRD pattern, a representative example of which is provided in the diffractogram of FIG. 4 .
  • Particular characteristic peaks occur at 9.0, 13.9, 14.8, 21.5, 24.7, and 29.8 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 17.0, 20.6, 20.8, 22.4, 25.8, 27.7, 28.4, 28.7, 29.1, 30.8, 3.19, 32.3, and 32.9 ⁇ 0.2° 2 ⁇ .
  • the hydration level of Zoledronic acid form XII is indicated by a LOD of about 6-10%, preferably 6% (monohydrate) on heating from about 25-220° C.
  • Zoledronic acid Form XII can be prepared by treating Zoledronic acid form XVIII in water at reflux temperature, the diluent/solid ratio being 10-30 volumes, preferably 24-26 volumes, and cooling the solution to room temperature or less.
  • Zoledronic Form XII can be also be prepared by stirring Form I in acetic acid.
  • the invention provides a novel crystalline solid form of Zoledronic acid denominated Form XV.
  • Zoledronic acid Form XV can be identified by its PXRD pattern, a representative example of which is provided in FIG. 5 . Particular characteristic peaks occur at 10.1, 17.3, 19.3, and 23.2 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 14.5, 16.7, 18.1, 24.5, 25.1, 25.7, 28.5, 29.1, 29.6, and 30.4 ⁇ 0.2° 2 ⁇ .
  • the TGA of form XV shows a LOD of 1% (anhydrous) within the temperature range 25-220° C.
  • Zoledronic acid Form XV can be prepared by treating any form of Zoledronic acid (preferably form I) and sodium hydroxide (1:1 mole ratio) in absolute ethanol (10 volumes per grams of ZLD-Ac) at reflux temperature for a duration of 5-20 hours, most preferably 10-16 hours.
  • Zoledronic acid Form XV can also be prepared by treating any form of Zoledronic acid (preferably form I or form XII) and sodium hydroxide (1:1 mole ratio) in methanol (10 volumes per grams of ZLD-Ac) at reflux temperature for a duration of 5-20 hours, most preferably 10-16 hours.
  • any form of Zoledronic acid preferably form I or form XII
  • sodium hydroxide (1:1 mole ratio
  • the invention provides a novel crystalline solid form of Zoledronic acid denominated Form XVIII.
  • Zoledronic acid Form XVIII can be identified by its PXRD pattern, a representative example of which is provided in FIG. 6 . Particular characteristic peaks occur at 10.7, 13.0, 16.4, 17.4, and 28.5 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 13.3, 18.1, 19.3, 21.3, 23.7, 25.9, 31.5, and 34.5 ⁇ 0.2° 2 ⁇ .
  • the TGA weight loss curve of Zoledronic acid form XVIII shows a LOD between 0.3% and about 6%, preferably 6% (monohydrate) within the temperature range 25-220° C.
  • Zoledronic acid Form XVIII can be prepared by a reaction of 1-Imidazoleacetic acid, Phosphorous acid and Silicon oil. Phosphorous oxychloride is added to the reaction mixture at 80° C. and the reaction mixture is stirred at this temperature for 22 hours. The aqueous phase is separated after addition of water and heated to reflux temperature for a 16 hours. Then absolute ethanol is added and the solution is kept at reflux temperature for 2 hours. Then the solution is cooled gradually to 25° C. to obtain a precipitate of ZLD-Ac.
  • Zoledronic acid Form XVIII can be also prepared by treating Zoledronic acid form I in methanol, 1-butanol, MTBE, acetonitrile, methanol/water 1:1 or ethanol water 1:1 (10 volumes per grams of ZLD-Ac), at room temperature or reflux temperature, for a duration of 5-20 hours, most preferably 10-16 hours.
  • the invention provides a novel crystalline solid form of Zoledronic acid denominated Form XX.
  • Zoledronic acid Form XX can be identified by its PXRD pattern, a representative example of which is provided in FIG. 7 . Particular characteristic peaks occur at 12.2, 19.3, 20.2, 21.3, 25.1, and 27.2 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 11.4, 14.9, 15.5, 17.2, 18.2, and 30.5 ⁇ 0.2° 2 ⁇ .
  • the TGA weight loss curve of Zoledronic acid form XX shows a LOD of about 0.5% (anhydrous) within the temperature range 25-220° C.
  • Zoledronic acid Form XX can be prepared by treating Zoledronic acid form I in ethanol, (preferably absolute), 1-propanol, 2-propanol (IPA), preferably at reflux temperature, the diluent/solid ratio being 15-25 volumes, preferably 10 volumes, for a duration of 5-20 hours, most preferably 10-16 hours.
  • the invention provides a novel crystalline solid form of Zoledronic acid, denominated Form XXVI.
  • Zoledronic acid Form XXVI can be identified by its PXRD pattern, a representative example of which is provided in FIG. 8 . Particular characteristic peaks occur at 9.8, 14.5, 17.1, 17.6, and 18.3 ⁇ 0.2° 2 ⁇ . Additional peaks occur at 18.8, 19.7, 21.4, 25.7, 26.6, and 28.1 ⁇ 0.2° 2 ⁇ .
  • the TGA weight loss curve of Zoledronic acid form XXVI shows typically a LOD of about 1.3% (anhydrous) within the temperature range 25-220° C.
  • Zoledronic acid Form XXVI can be prepared by treating Zoledronic acid form I in 2-butanol, preferably at reflux temperature.
  • the diluent/solid ratio being 15-25 volumes, preferably 10 volumes, for a duration of 5-20 hours, most preferably 10-16 hours.
  • Zoledronic acid sodium salt in a crystalline form could be obtained.
  • Use of salts in drugs is very diffused, due to the improved physico-chemical properties over the free acid or free base, mainly solubility or crystallinity properties.
  • the crystalline state of a drug in general, has an advantage over the amorphous state in that the physical (and chemical) properties are fully controlled and reproduced, and the capability of a material to crystallize in a solid form makes this material feasible for pharmaceutical uses.
  • the novel crystalline Zoledronate sodium salt may have improved solubility.
  • the sodium salts obtained have a purity of at least 99.9% area by HPLC.
  • Zoledronate sodium salt can crystallize in different crystal forms.
  • the level of sodium is measured by methods known in the art, like atomic absorption.
  • Zoledronate sodium can be found in a monosodium salt, disodium salt, trisodium salt, each of them in various hydration states.
  • the Zoledronate monosodium salt has a sodium content in the range of 6-8% w/w.
  • Zoledronate disodium has a sodium content in the range of 11-13% w/w, and Zoledronate trisodium has a sodium content in the range of 17-19% w/w.
  • the level of water in Zoledronate sodium is estimated by TGA (thermogravimetric analysis) weight loss.
  • the Zoledronate sodium salt can be anhydrous (weight loss up to 2%), a hemihydrate (weight loss 3-4% w/w), a monohydrate (weight loss 5-6%), a sesquihydrate (weight loss 7-8%), a dihydrate (weight loss 9-12% w/w), a trihydrate (13-16% weight loss), or a tetrahydrate (weight loss 17-19% w/w).
  • sodium salts of Zoledronic acid may be prepared by treating Zoledronic acid with a base, preferably NaOH, in organic solvents, like lower alcohols or DMF, and water in different proportions relative to the organic solvent.
  • the reaction is preferably carried out at reflux temperature.
  • a solution of a base in a mixture of alcohol/water is added to a suspension of Zoledronic acid in an equivalent mixture of alcohol/water at reflux temperature.
  • the volume ratio of diluent/Zoledronic acid is 6-14, preferably 10 volumes.
  • the reaction mixture is stirred at reflux temperature for 10-20 hours, preferably 14-16 hours.
  • the reaction mixture can be cooled to room temperature or less, and filtered, or filtered at higher temperatures.
  • sodium salts of Zoledronic acid may be prepared by dissolving Zoledronic acid in water, adding a base, preferably NaOH, and precipitating it by cooling, optionally with the aid of an organic solvent such as isopropol alcohol.
  • sodium salts of Zoledronic acid may be recrystallized by treating the sodium salt of Zoledronic acid in water (20-30 volumes, preferably 25 volumes) at reflux temperature and then cooling the solution to less than room temperature to obtain a precipitate of ZLD-Na.
  • Zoledronate monosodium can be found in crystal Form VIII, characterized by typical PXRD peaks at 8.2, 15.5, 18.6, 23.6, 26.8 deg. 2-theta, and additional peaks at 11.8, 17.6, 20.1, 24.7, 25.0, 28.4, 31.7, 32.8 deg. 2-theta.
  • the TGA of form VIII shows a weight loss of 15-16% (trihydrate) within the temperature range 25-220° C.
  • Zoledronate monosodium can be found in crystal form XVI, characterized by typical XRD peaks at 7.3, 8.8, 14.7, 21.8, 29.6 deg. 2-theta, and additional peaks at 13.8, 16.8, 20.4, 21.4, 24.4, 25.6, 27.5, 28.2, 31.7 deg.2-theta.
  • the TGA curve of form XVI shows a weight loss of 9-10% (dihydrate) within the temperature range 25-220° C.
  • Zoledronate monosodium can be found in crystal form XVII, characterized by typical XRD peaks at 8.2, 9.0, 14.5, 21.4, 24.5, 29.2 deg 2-theta, and additional peaks at 13.9, 15.5, 16.8, 18.6, 22.3, 23.6, 26.7, 27.7, 32.3 deg. 2-theta.
  • the TGA of form XVII shows a weight loss of about 10% (dihydrate) within the temperature range 25-220° C.
  • Zoledronate monosodium form VIII may be prepared by dissolving Zoledronic acid in water, adding NaOH in pellets or in aquous solution (40%). IPA may be added to improve the yield of crystallization. This solution is cooled to get form VIII.
  • Zoledronate monosodium form VIII may be also obtained by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:1) in water/ethanol 80%:20% v/v, water/methanol 80%:20% v/v, water/isopropanol 80%:20% v/v or 60%:40% v/v.
  • Zoledronate monosodium form XVI may be obtained by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:1) in water/ethanol 50%:50% v/v or water/isopropanol 50%:50% v/v, or water/methanol 50%:50% v/v.
  • Zoledronate monosodium form XVII may be obtained by dissolving Zoledronic acid in water, adding NaOH in aqueous solution (29%) drop-wise (ratio of acid/base 1:0.7)
  • Zoledronate disodium can be found in form V, characterized by typical peaks at 11.3, 14.8, 15.5, 17.4, 19.9 deg. 2-theta, and additional peaks at 18.0, 18.9, 19.7, 22.7, 25.0, 26.7, 30.9, 34.5 deg. 2-theta.
  • the TGA curve of form V shows a weight loss of about 10-11% (dihydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form V may be prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1.1) in water/ethanol ratios between 20%-50% v/v water in ethanol, water/methanol ratios between 40%-50% v/v water in methanol, water/IPA ratios between 40%-50% v/v water in IPA.
  • Zoledronate disodium form V may also be prepared by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base1:2) in water/ethanol ratios between 20%-50% v/v water in ethanol, water/methanol 50%:50% v/v water in methanol, water/isopropanol ratios between 20%-50% v/v water in IPA.
  • Zoledronate disodium form V may also be prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acidibase 1:1.1) in water/ethanol ratios between 20%-50% v/v water in ethanol, water/methanol ratios between 40%-50% v/v water in methanol, water/IPA ratios between 40%-50% v/v water in EPA.
  • Zoledronic acid preferably form XII
  • sodium hydroxide ratio of acidibase 1:1.1
  • Zoledronate disodium can be found in form VI, characterized by typical peaks at 7.2, 13.3, 13.7, 14.5, 21.7 deg. 2-theta, and additional peaks at 8.2, 16.6, 16.9, 17.3, 25.9, 26.6, 30.7, 31.9, 32.9 deg. 2-theta.
  • the TGA curve of form VI shows a weight loss of 13-16% (trihydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form VI may be prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1.1) in water/ethanol or water/methanol 60% v/v water in ethanol or methanol, or water/isopropanol 80% v/v water in IPA.
  • Zoledronate disodium form VI may also be obtained also by recrystallizing Zoledronate disodium, preferably form XIX, in water.
  • Zoledronate disodium can be found in form VII, characterized by typical peaks at 6.2 11.6, 12.6, 13.7 deg. 2-theta, and additional peaks at 22.0, 23.2, 26.4, 27.1, 28.6, 28.8, 34.2 deg. 2-theta.
  • the TGA curve of form VII shows a weight loss of 17-19% within the temperature range 25-220° C. (tetrahydrate). Less crystalline form VII is found with water content of 7-10% within the temperature range 25-220° C.
  • Zoledronate sodium form VII may be obtained by dissolving Zoledronic acid in water, adding a base, preferaby NaOH (aqueous solution or pearls) until the pH of 5.5-7.5, preferably 5.7-7.0.
  • the solution is cooled and optionally an organic solvent (preferably isopropanol) is added.
  • the solution may be concentrated to obtain the solid material.
  • the mixture may be further stirred for a period of 1-5 hours, preferably 2 hours.
  • Zoledronate disodium form VII may be also prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1.1) in water/ethanol or water/methanol or water/isopropanol 80%:20% v/v of water in the alcohol.
  • Zoledronate disodium form VII may be also prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1.1) in water/isopropanol 60%:40% v/v water in IPA.
  • Zoledronate disodium form VII may be also prepared by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:2) in water/ethanol 80%:20% v/v water in ethanol.
  • Zoledronate disodium can be found in form X, characterized by typical peaks at 6.7, 14.4, 18.2, 20.4, 20.7 deg. 2-theta, and additional peaks at 8.8, 13.7, 17.0, 19.8, 21.3, 24.4, 27.5, 27.9, 30.9, 33.4 deg. 2-theta.
  • the TGA curve of form X shows a weight loss of about 3% (hemihydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form X may be obtained by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1.1) in water/isopropanol 20%:80% v/v water in IPA.
  • Zoledronate disodium can be found in form XIII, characterized by typical peaks at 6.5, 13.0, 16.1, 17.2, 30.7 deg. 2-theta, and additional peaks at 10.2, 19.0, 20.0, 20.6, 22.3, 27.4, 28.6, 28.9, 34.8 deg. 2-theta.
  • the TGA curve of form XIII shows a weight loss of about 3% (hemihydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form XIII may be obtained by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:2) in water/ethanol 5%:95% v/v water in ethanol.
  • Zoledronate disodium can be found in form XIV, characterized by typical peaks at 6.6, 19.9, 28.5, 34.8 deg. 2-theta, and additional peaks at 13.0, 15.1, 17.1, 20.5, 27.7, 29.6, 30.7, 33.5 deg. 2-theta.
  • the TGA curve of form XIV shows a weight loss of 1-2% (anhydrous) within the temperature range 25-220° C.
  • Zoledronate disodium form XIV may be obtained by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:2) in water/methanol 20%:80% v/v water in methanol.
  • Zoledronate disodium form XIV may be also obtained by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1) in water/DMF 20%:80% v/v water in DMF.
  • Zoledronate disodium can be found in form XIX, characterized by typical X-Ray peaks at 11.6, 12.5, 13.7, 22.0, 23.1 deg. 2-theta, and additional peaks at 6.2, 14.3, 15.3, 16.0, 18.5, 24.3, 28.6 deg. 2-theta.
  • the TGA curve of form XIX shows a weight loss of about 22% (pentahydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form XIX may be obtained by treating Zoledronate disodium, preferably form VII, in water and precipitating the material, preferably by cooling.
  • Zoledronate disodium form XIX may be also obtained by dissolving Zoledronic acid in water, adding a base, preferably NaOH (aqueous solution or pearls) (ratio of acid/base 1:2), in reflux.
  • a base preferably NaOH (aqueous solution or pearls) (ratio of acid/base 1:2), in reflux.
  • Zoledronate disodium can be found in form XXV, characterized by typical peaks at 7.4, 13.7, 17.6, 21.9 deg. 2-theta, and additional peaks at 6.3, 9.5, 12.6, 14.6, 26.2, 27.1, 28.6 deg. 2-theta.
  • the TGA curve of form XXV shows a weight loss of 7-8% (sesquihydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form XXV may be obtained by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:2) in water/methanol 80%:20% v/v water in methanol.
  • Zoledronate disodium can be found in form XXVII, characterized by typical peaks at 6.4, 8.2, 16.0, 17.4, 19.0, 28.8 deg. 2-theta, and additional peaks at 7.7, 10.2, 17.2, 18.1, 21.6, 25.7, 25.9 deg. 2-theta.
  • the TGA curve of form XXVII shows a weight loss of about 5-6% (monohydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form XXVII may be prepared by treating Zoledronic acid, preferably form I, and sodium hydroxide (ratio of acid/base 1:2) in water/methanol 5%:95% v/v water in methanol and by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:1) in water/methanol 20%:80% v/v water in methanol.
  • Zoledronate trisodium can be found in form IX, characterized by typical peaks at 8.3, 10.9, 15.0, 16.6, 22.8 deg. 2-theta, and additional peaks at 13.1, 20.2, 20.6, 20.9, 25.0, 27.8, 29.0 deg. 2-theta.
  • the TGA curve of form IX shows a weight loss of about 13-14% (trihydrate) within the temperature range 25-220° C.
  • Zoledronate trisodium form IX may be prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:2.1) in water/ethanol or water/methanol or water/isopropanol in ratios between 20%-80% v/v of water in the alcohol.
  • Zoledronate trisodium can be found in form XI, characterized by typical peaks at 6.2, 7.9, 8.8, 10.6, 12.2 deg. 2-theta, and additional peaks at 15.0, 15.4, 17.5, 18.8, 19.6, 20.5, 22.3, 23.7, 25.7, 29.6, 31.7 deg. 2-theta.
  • the TGA curve of form XI shows a weight loss of about 9% (dihydrate) within the temperature range 25-220° C.
  • Zoledronate disodium form XI may be prepared by treating Zoledronic acid, preferably form XII, and sodium hydroxide (ratio of acid/base 1:2.1) in water/ethanol or water/methanol 5%:95% v/v of water in ethanol or methanol.
  • Zoledronate sodium amorphous is prepared by treating Zoledronic acid and sodium hydroxide (ratio of acid/base 1:1.1 or 1:2.1 or 1:3.1) in water at room temperature, and precipitating the material by concentrating the solution by any means known in the art like evaporation of the solvent. Evaporation may be done using a vacuum.
  • IAA 1-Imidazoleacetic acid
  • Phosphorous acid Phosphorous acid
  • a diluent Toluene/Chlorobenzene/PEG-400/Silicon oil.
  • the obtained suspension is heated to 75° C.-80° C. and Phosphorous oxychloride is added drop-wise.
  • the reaction mixture is then heated to 75° C.-100° C. for 1-34 hours.
  • water is added at 80° C.-100° C.
  • the mixture is stirred vigorously for about 15 minutes.
  • the suspension was heated to 75° C. and phosphorous oxychloride (10.5 ml, 0.11 mole) was added drop-wise during 30 minutes.
  • the reaction mixture was then heated to 80° C. for 27 hours.
  • water (27 ml) and toluene (30 ml) were added at 80° C. The mixture was stirred vigorously for about 15 minutes.
  • Zoledronic acid crystal form I (2.0 g) was stirred in Toluene (20 ml) at reflux temperature for 14 hours. Then the suspension was cooled to room temperature, filtered, washed with Toluene (1 ⁇ 15 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.6 g of Zoledronic acid crystal form II.
  • Zoledronic acid crystal form XVIII (10.0 g) was dissolved in water (260 ml) at reflux temperature. The obtained solution was stirred at reflux temperature for about 20 minutes to obtain a clear solution. Then it was cooled to 75° C. during 2 hours and stirred at this temperature for 1 hour. The turbid solution was further cooled to 25° C. during 4.5 hours and stirred at this temperature for 1 hour. After cooling to 0° C. during 2 hours and stirring at this temperature for 16 hours, the white precipitate was filtered and dried in a vacuum oven at 50° C. for 24 hours to obtain 7.8 g of Zoledronic acid crystal form XII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in Acetic acid (20 ml) at room temperature for 15.5 hours. Then it was filtered, washed with Acetic acid (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 2.0 g of Zoledronic acid crystal form XII.
  • Zoledronic acid crystal form XII (2.0 g) was stirred in Methanol (20 ml) at reflux temperature for 19 hours. Then the suspension was cooled to room temperature, filtered, washed with Methanol (1 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.8 g of a mixture of Zoledronic acid crystal forms XV and XVIII.
  • the suspension was heated to 80° C. and Phosphorous oxychloride (194.4 ml, 2.08 mole) was added drop-wise during 4 hours.
  • the reaction mixture was stirred at 80° C. for 22 hours.
  • water (490 ml) was added slowly at 80° C. The mixture was stirred vigorously for about 30 minutes. Then the silicon oil phase and the aqueous phase were separated.
  • Zoledronic acid crystal form I (2.0 g) was stirred in Methanol (20 ml) at room temperature for 14.5 hours. Then it was filtered, washed with Methanol (2 ⁇ 10 ml) and dried in a vacuum oven at 50° C. for 25 hours to obtain 1.9 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in Methanol (20 ml) at reflux temperature for 16 hours. Then the suspension was cooled to room temperature and the white solid was filtered, washed with Methanol (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.7 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in 1-Butanol (20 ml) at reflux temperature for 15.5 hours. Then the suspension was cooled to room temperature and the white solid was filtered, washed with 1-Butanol (1 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.8 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in MTBE (20 ml) at reflux temperature for 15 hours. Then the suspension was cooled to room temperature and the white solid was filtered, washed with MTBE (1 ⁇ 10 ml) and dried in a vacuum oven at 50° C. for 25 hours to obtain 1.4 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in Acetonitrile (20 ml) at room temperature for 22 hours. Then the suspension was filtered, washed with Acetonitrile (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 23 hours to obtain 2.0 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in a mixture of Methanol/water (1:1 v/v) (20 ml) at reflux temperature for 18 hours. Then the suspension was cooled to 0° C., filtered and dried in a vacuum oven at 50° C. for 22 hours to obtain 1.8 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in a mixture of Ethanol/water (1:1 v/v) (20 ml) at reflux temperature for 18 hours. Then the suspension was cooled to 0° C., filtered and dried in a vacuum oven at 50° C. for 22 hours to obtain 1.8 g of Zoledronic acid crystal form XVIII.
  • Zoledronic acid crystal form I (2.0 g) was stirred in absolute Ethanol (20 ml) at reflux temperature for 16 hours. The suspension was then cooled to room temperature and the white solid was filtered, washed with absolute Ethanol (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 22.5 hours to obtain 1.9 g of Zoledronic acid crystal form XX in a mixture with crystal form I.
  • Zoledronic acid crystal form I (2.0 g) was stirred in 1-Propanol (20 ml) at reflux temperature for 11.5 hours. The suspension was then cooled to room temperature and the white solid was filtered, washed with 1-Propanol (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.9 g of Zoledronic acid crystal form XX.
  • Zoledronic acid crystal form I (2.0 g) was stirred in 2-Propanol (IPA) (20 ml) at reflux temperature for 14 hours. The suspension was then cooled to room temperature and the white solid was filtered, washed with IPA (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.9 g of Zoledronic acid crystal form XX. Purity by HPLC 99.8%.
  • IPA 2-Propanol
  • Zoledronic acid crystal form I (2.0 g) was stirred in 2-Butanol (20 ml) at reflux temperature for about 15 hours. The suspension was then cooled to room temperature and the white solid was filtered, washed with 2-Butanol (2 ⁇ 5 ml) and dried in a vacuum oven at 50° C. for 24 hours to obtain 1.9 g of Zoledronic acid crystal form XXVI.
  • a 0.5 L reactor equipped with a mechanical stirrer, a thermometer, a reflux condenser and a dropping funnel, was loaded with Zoledronic acid form I (10.0 g) and water (247 ml). The suspension was heated to 94° C. to obtain a clear solution. A 40% aqueous solution of Sodium hydroxide (3.45 g) was added drop-wise. The solution was then cooled to 4° C. during 2 hours and was stirred at this temperature for about 64 hours to obtain a massive precipitate. The white precipitate was filtered, washed with cold water (1 ⁇ 10 ml) and dried in a vacuum oven at 50° C. for 26 hours to obtain 7.6 g (64%) of Zoledronate monosodium crystal form VIII (LOD by TGA 15.1%).
  • the composition of the reflux media is expressed on a volume per volume basis (abbreviated v/v).
  • a solution of sodium hydroxide (0.7 g) in a mixture of water (60% v/v)/IPA (40% v/v, 10 volumes per grams of ZLD-Ac form I) (19 ml) was added drop-wise to a suspension of Zoledronic acid (5.0 g) in a mixture of water (60% v/v)/IPA (40% v/v, 10 volumes per grams of ZLD-Ac form I) (106 ml) at reflux temperature. The reaction mixture was heated at reflux temperature for additional 16 hours. Then the reaction mixture was cooled to room temperature. Further cooling was performed using an ice-bath. The precipitate was then filtered, washed with IPA (1 ⁇ 20 ml) and dried in a vacuum oven at 50° C. for 27 hours to give 0.6 g (10%) of Zoledronate monosodium crystal form VIII (LOD by TGA 15.0%).
  • a 0.5 L reactor equipped with a mechanical stirrer, a thermometer, a reflux condenser and a dropping funnel, was loaded with Zoledronic acid form I (10.0 g) and water (247 ml). The suspension was heated to 94° C. to obtain a clear solution. A 29% aqueous solution of Sodium hydroxide (3.45 g) was added drop-wise. The solution was then cooled to room temperature and stirred at this temperature for 16 hours. After cooling to 3° C. the product was isolated by filtration. Further cooling of the mother-liquid led to the formation of a white precipitate. The precipitate was filtered and dried in a vacuum oven at 50° C. for 24 hours to obtain 0.6 g of Zoledronate monosodium crystal form XVII (LOD by TGA 10.3%).
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (80% v/v) IPA (20% v/v, 10 volumes per grams of ZLD-Ac form D) (38 ml) was added drop-wise to a suspension of Zoledronic acid form I (5.0 g) in a mixture of water (80% v/v)/IPA (20% v/v, 10 volumes per grams of ZLD-Ac) (212 ml) at reflux temperature. The reaction mixture was heated at reflux temperature for additional 16 hours. Then the reaction mixture was cooled to room temperature and the solution was evaporated to dryness. The obtained solid was dried in a vacuum oven at 50° C. for 5 hours to give 5.2 g (78%) of Zoledronate disodium crystal form VI (LOD by TGA 15.4%).Purity by HPLC 99.9%.
  • Zoledronate disodium crystal form XIX (4.0 g) was dissolved in water (10 ml) at reflux temperature. After about 30 minutes at reflux temperature a precipitate was obtained. The suspension was then cooled to 0° C. using an ice-bath. The solid was isolated by filtration and dried in a vacuum oven at 50° C. for 17 hours to give 2.0 g (50%) of Zoledronate disodium crystal form VI.
  • a 0.5 L reactor equipped with a mechanical stirrer, a thermometer, a reflux condenser and a dropping funnel, was loaded with Zoledronic acid form I (10.0 g) and water (130 ml). The suspension was heated to reflux temperature to obtain a clear solution. A 40% aqueous solution of Sodium hydroxide (6.9 g) was added drop-wise. The solution was then cooled to 4° C. during 2 hours and was stirred at this temperature for about 1.5 hours. The solution was concentrated to half of its volume to obtain a precipitate. The white precipitate was filtered and dried in a vacuum oven at 50° C. for 22 hours to obtain 2.7 g (22%) of Zoledronate disodium crystal form VII (LOD by TGA 10.7%).
  • a 0.5 L reactor equipped with a mechanical stirrer, a thermometer, a reflux condenser and a dropping funnel, was loaded with Zoledronic acid form I (10.0 g) and water (130 ml). The suspension was heated to reflux temperature (92° C.) to obtain a clear solution. A 40% aqueous solution of Sodium hydroxide (6.9 g) was added drop-wise. The solution was then cooled to 25° C. was stirred at this temperature for about 16 hours. The solution was then concentrated to half of its volume to obtain a precipitate. The white precipitate was filtered and dried in a vacuum oven at 50° C. for 18.5 hours to obtain 2.8 g (23%) of Zoledronate disodium crystal form VII (LOD by TGA 10.2%). Purity by HPLC 100.0%.
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (80% v/v)/Ethanol (20% v/v, 10 volumes per grams of ZLD-Ac form I) (38 ml) was added drop-wise to a suspension of Zoledronic acid form I (5.0 g) in a mixture of water (80% v/v)/Ethanol (20% v/v, 10 volumes per grams of ZLD-Ac) (212 ml) at reflux temperature. The reaction mixture was heated at reflux temperature for additional 18.5 hours. Then the reaction mixture was cooled to room temperature and the solution was evaporated to dryness to obtain 6.7 g (98%) of Zoledronate disodium crystal form VII (LOD by TGA 16.8%). Purity by HPLC 99.9%.
  • Zoledronate disodium crystal form VII (1.0 g) was dissolved in water (19 ml) at reflux temperature. After about 30 minutes at reflux temperature a light precipitate was obtained. The suspension was then cooled to 0° C. using an ice-bath and was concentrated under vacuum to obtain a massive precipitation. The solid was isolated by filtration after further stirring at 0° C., and dried in a vacuum oven at 50° C. for 27 hours to give 0.4 g (40%) of Zoledronate disodium crystal form XIX.
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (80% v/v)/Methanol (20% v/v, 10 volumes per grams of ZLD-Ac form I) (38 ml) was added drop-wise to a suspension of Zoledronic acid form I (5.0 g) in a mixture of water (80% v/v)/Methanol (20% v/v, 10 volumes per grams of ZLD-Ac) (212 ml) at reflux temperature. The reaction mixture was heated at reflux temperature for additional 19 hours. Then the reaction mixture was cooled to room temperature. Further cooling was performed using an ice-bath. The solution was then evaporated to dryness to obtain 6.1 g (99%) of Zoledronate disodium crystal form XXV (LOD by TGA 7.4%). Purity by HPLC 99.9%.
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (20% v/v)/Ethanol or Methanol or IPA (80% v/v, 10 volumes per grams of ZLD-Ac form XII) (10 ml) was added drop-wise to a suspension of Zoledronic acid form XII (5.0 g) in a mixture of water (20% v/v)/Ethanol or Methanol or IPA (80% v/v, 10 volumes per grams of ZLD-Ac) (53 ml) at reflux temperature.
  • the reaction mixture was heated at reflux temperature for additional 16 hours. Then the reaction mixture was cooled to room temperature. Further cooling was performed using an ice-bath.
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (40% v/v)/Ethanol or Methanol or IPA (60% v/v, 10 volumes per grams of ZLD-Ac form XII) (13 ml) was added drop-wise to a suspension of Zoledronic acid form XII (5.0 g) in a mixture of water (40% v/v)/Ethanol or Methanol or IPA (60% v/v, 10 volumes per grams of ZLD-Ac) (71 ml) at reflux temperature.
  • the reaction mixture was heated at reflux temperature for additional 16 hours. Then the reaction mixture was cooled to room temperature. Further cooling was performed using an ice-bath.
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (60% v/v)/Ethanol or Methanol or IPA (40% v/v, 10 volumes per grams of ZLD-Ac form XII) (19 ml) was added drop-wise to a suspension of Zoledronic acid form XIII (5.0 g) in a mixture of water (60% v/v)/Ethanol or Methanol or IPA (40% v/v, 10 volumes per grams of ZLD-Ac) (106 ml) at refiux temperature.
  • the reaction mixture was heated at reflux temperature for additional 16 hours. Then the reaction mixture was cooled to room temperature. Further cooling was performed using an ice-bath.
  • a solution of sodium hydroxide (1.4 g) in a mixture of water (80% v/v)/Ethanol or Methanol or EPA (20% v/v, 10 volumes per grams of ZLD-Ac form XII) (38 ml) was added drop-wise to a suspension of Zoledronic acid form XII (5.0 g) in a mixture of water (80% v/v)/Ethanol or Methanol or IPA (20% v/v, 10 volumes per grams of ZLD-Ac) (212 ml) at reflux temperature.
  • the reaction mixture was heated at reflux temperature for additional 16 hours. Then the reaction mixture was cooled to room temperature. Further cooling was performed using an ice-bath.
US10/886,099 2003-07-03 2004-07-06 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation Abandoned US20050054616A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/886,099 US20050054616A1 (en) 2003-07-03 2004-07-06 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,362 US20070021619A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,258 US7582768B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,348 US7589211B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,255 US7687636B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,083 US20070021616A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,254 US7435827B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48487603P 2003-07-03 2003-07-03
US10/886,099 US20050054616A1 (en) 2003-07-03 2004-07-06 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US11/527,083 Division US20070021616A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,348 Division US7589211B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,362 Division US20070021619A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,254 Division US7435827B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,255 Division US7687636B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,258 Division US7582768B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation

Publications (1)

Publication Number Publication Date
US20050054616A1 true US20050054616A1 (en) 2005-03-10

Family

ID=34062065

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/886,099 Abandoned US20050054616A1 (en) 2003-07-03 2004-07-06 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,254 Expired - Fee Related US7435827B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,258 Expired - Fee Related US7582768B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,362 Abandoned US20070021619A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,255 Expired - Fee Related US7687636B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,348 Expired - Fee Related US7589211B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,083 Abandoned US20070021616A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation

Family Applications After (6)

Application Number Title Priority Date Filing Date
US11/527,254 Expired - Fee Related US7435827B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,258 Expired - Fee Related US7582768B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,362 Abandoned US20070021619A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,255 Expired - Fee Related US7687636B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,348 Expired - Fee Related US7589211B2 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US11/527,083 Abandoned US20070021616A1 (en) 2003-07-03 2006-09-25 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation

Country Status (8)

Country Link
US (7) US20050054616A1 (fr)
EP (2) EP1612212A1 (fr)
AT (1) ATE425170T1 (fr)
CA (1) CA2530193A1 (fr)
DE (1) DE602004019881D1 (fr)
ES (1) ES2322592T3 (fr)
IL (1) IL172513A0 (fr)
WO (1) WO2005005447A2 (fr)

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188542A1 (en) * 2005-02-22 2006-08-24 Bobyn John D Implant improving local bone formation
WO2006134603A1 (fr) 2005-06-13 2006-12-21 Jubilant Organosys Limited Procédé de production d’acides bisphosphoniques et de formes de ceux-ci
WO2007016982A1 (fr) 2005-07-28 2007-02-15 Gador S.A. Forme cristalline de l'acide zoledronique, son procede d'obtention et composition pharmaceutique la renfermant
WO2007069049A2 (fr) * 2005-12-16 2007-06-21 Wockhardt Ltd Procedes pour la preparation d'acide zoledronique pur
WO2007125521A2 (fr) * 2006-05-02 2007-11-08 Ranbaxy Laboratories Limited Formes polymorphiques de l'acide zolédronique et leurs procédés de synthèse
EP1925621A1 (fr) * 2006-11-27 2008-05-28 Novartis AG Formes cristallines de l'acide zolédronique
US20110028435A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20110172632A1 (en) * 2009-12-23 2011-07-14 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9522157B2 (en) 2012-05-14 2016-12-20 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9539268B2 (en) 2014-05-27 2017-01-10 Antecip Bioventures Ii Llc Therapeutic compositions comprising imidazole and imidazolium compounds
US9585902B2 (en) 2012-05-14 2017-03-07 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9623036B2 (en) 2014-08-08 2017-04-18 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
KR101739244B1 (ko) * 2013-10-25 2017-05-23 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10093691B2 (en) 2009-07-31 2018-10-09 Grunenthal Gmbh Crystallization method and bioavailability
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US10173986B2 (en) * 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
US20190083407A1 (en) * 2015-09-18 2019-03-21 Grunenthal Gmbh Crystallization method and bioavailability
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
EP2041148A1 (fr) * 2006-07-03 2009-04-01 Generics Ýuk¨Limited Nouveau procédé pour la préparation d'acides bisphosphoniques
EP3158867B1 (fr) 2009-07-31 2018-12-12 Grünenthal GmbH Un procédé pour augmenter la solubilite aqueuse d'un acide bisphosphonique ou d'un bisphosphonate
CA2826548A1 (fr) * 2010-02-06 2011-08-11 Thar Pharmaceuticals, Inc. Procede de cristallisation et biodisponibilite
PT2849758T (pt) * 2012-05-14 2018-05-09 Antecip Bioventures Ii Llc Composições que compreendem o ácido zoledrónico ou compostos relacionados para o alívio da dor inflamatória e estados relacionados
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
US9127069B1 (en) * 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
JP2016142045A (ja) * 2015-02-02 2016-08-08 アイシン精機株式会社 開閉体開閉装置
WO2017195031A1 (fr) 2016-05-13 2017-11-16 Grunenthal Gmbh Nouvelles formes cristallines
US10316823B2 (en) * 2017-03-15 2019-06-11 Inventus Holdings, Llc Wind turbine group control for volant animal swarms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939130A (en) * 1986-11-21 1990-07-03 Ciba-Geigy Corporation Substituted alkanediphosphonic acids and pharmaceutical use
US20020193603A1 (en) * 1994-05-18 2002-12-19 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US20040077683A1 (en) * 2001-06-18 2004-04-22 Reddy M. Satyanarayana Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1- piperidinyl]-1-hydroxybutyl]-$g(a)-dimethylbenzene acetic acid and its hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212917A (en) 1984-08-22 1988-08-30 Apace Res Ltd Recovering alcohols from solution
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5728650A (en) * 1993-10-07 1998-03-17 Zeneca Limited Herbicidal aza bisphosphonic acids and compositions containing the same
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
ATE524434T1 (de) * 2003-01-03 2011-09-15 Ineos Usa Llc Verfahren zur rückgewinnung von acrylnitril und methacrylnitril

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939130A (en) * 1986-11-21 1990-07-03 Ciba-Geigy Corporation Substituted alkanediphosphonic acids and pharmaceutical use
US20020193603A1 (en) * 1994-05-18 2002-12-19 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US20040077683A1 (en) * 2001-06-18 2004-04-22 Reddy M. Satyanarayana Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1- piperidinyl]-1-hydroxybutyl]-$g(a)-dimethylbenzene acetic acid and its hydrochloride

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20110014265A1 (en) * 2005-02-22 2011-01-20 John Dennis Bobyn Implant Improving Local Bone Formation
US20060188542A1 (en) * 2005-02-22 2006-08-24 Bobyn John D Implant improving local bone formation
US8309536B2 (en) 2005-02-22 2012-11-13 John Dennis Bobyn Implant improving local bone formation
US20090312551A1 (en) * 2005-06-13 2009-12-17 Satish Chandra Pandey Process for producing biphosphonic acids and forms thereof
WO2006134603A1 (fr) 2005-06-13 2006-12-21 Jubilant Organosys Limited Procédé de production d’acides bisphosphoniques et de formes de ceux-ci
US7872144B2 (en) 2005-06-13 2011-01-18 Jubilant Organosys Limited Process for producing biphosphonic acids and forms thereof
EP1891081A1 (fr) * 2005-06-13 2008-02-27 Jubilant Organosys Limited Procédé de production d acides bisphosphoniques et de formes de ceux-ci
EP1891081A4 (fr) * 2005-06-13 2009-11-04 Jubilant Organosys Ltd Procédé de production d acides bisphosphoniques et de formes de ceux-ci
WO2007016982A1 (fr) 2005-07-28 2007-02-15 Gador S.A. Forme cristalline de l'acide zoledronique, son procede d'obtention et composition pharmaceutique la renfermant
AU2006278951B2 (en) * 2005-07-28 2012-01-12 Gador S.A. A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
WO2007069049A2 (fr) * 2005-12-16 2007-06-21 Wockhardt Ltd Procedes pour la preparation d'acide zoledronique pur
WO2007069049A3 (fr) * 2005-12-16 2009-04-16 Wockhardt Ltd Procedes pour la preparation d'acide zoledronique pur
WO2007125521A3 (fr) * 2006-05-02 2008-01-10 Ranbaxy Lab Ltd Formes polymorphiques de l'acide zolédronique et leurs procédés de synthèse
WO2007125521A2 (fr) * 2006-05-02 2007-11-08 Ranbaxy Laboratories Limited Formes polymorphiques de l'acide zolédronique et leurs procédés de synthèse
EP1925621A1 (fr) * 2006-11-27 2008-05-28 Novartis AG Formes cristallines de l'acide zolédronique
JP2010510970A (ja) * 2006-11-27 2010-04-08 ノバルティス アーゲー ゾレドロン酸の結晶形
WO2008064849A1 (fr) * 2006-11-27 2008-06-05 Novartis Ag Formes cristallines de l'acide zolédronique
US8933057B2 (en) 2009-07-31 2015-01-13 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20110028435A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9334296B2 (en) 2009-07-31 2016-05-10 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US10323052B2 (en) 2009-07-31 2019-06-18 Grunenthal Gmbh Crystallization method and bioavailability
US10093691B2 (en) 2009-07-31 2018-10-09 Grunenthal Gmbh Crystallization method and bioavailability
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US20110172632A1 (en) * 2009-12-23 2011-07-14 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US10519176B2 (en) 2010-11-24 2019-12-31 Thar Pharma, Llc Crystalline forms
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9616077B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9623037B2 (en) 2012-05-14 2017-04-18 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9623038B2 (en) 2012-05-14 2017-04-18 Antecip Bioventures Ii Llc Osteoclast inhibitors for bone marrow lesions
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9522157B2 (en) 2012-05-14 2016-12-20 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9694022B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10420782B2 (en) 2012-05-14 2019-09-24 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9585901B2 (en) 2012-05-14 2017-03-07 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9855213B2 (en) 2012-05-14 2018-01-02 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9884069B2 (en) 2012-05-14 2018-02-06 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9931352B2 (en) 2012-05-14 2018-04-03 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9610300B2 (en) 2012-05-14 2017-04-04 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10265332B2 (en) 2012-05-14 2019-04-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US10039774B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10052338B2 (en) 2012-05-14 2018-08-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10238672B2 (en) 2012-05-14 2019-03-26 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9585902B2 (en) 2012-05-14 2017-03-07 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US10111891B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10111894B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10117880B2 (en) 2012-05-14 2018-11-06 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10137139B2 (en) 2012-05-14 2018-11-27 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10173986B2 (en) * 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10195141B2 (en) 2012-05-14 2019-02-05 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
KR101975687B1 (ko) * 2013-10-25 2019-05-07 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
KR101739244B1 (ko) * 2013-10-25 2017-05-23 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
KR20170058444A (ko) * 2013-10-25 2017-05-26 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10335424B2 (en) 2014-05-15 2019-07-02 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10195223B2 (en) 2014-05-15 2019-02-05 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9539268B2 (en) 2014-05-27 2017-01-10 Antecip Bioventures Ii Llc Therapeutic compositions comprising imidazole and imidazolium compounds
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9623036B2 (en) 2014-08-08 2017-04-18 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US20190083407A1 (en) * 2015-09-18 2019-03-21 Grunenthal Gmbh Crystallization method and bioavailability
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Also Published As

Publication number Publication date
US20070021618A1 (en) 2007-01-25
US7582768B2 (en) 2009-09-01
DE602004019881D1 (de) 2009-04-23
US20070027323A1 (en) 2007-02-01
EP1567533B1 (fr) 2009-03-11
US20070021616A1 (en) 2007-01-25
US7435827B2 (en) 2008-10-14
EP1567533A2 (fr) 2005-08-31
ES2322592T3 (es) 2009-06-23
US20070021617A1 (en) 2007-01-25
WO2005005447A2 (fr) 2005-01-20
EP1612212A1 (fr) 2006-01-04
CA2530193A1 (fr) 2005-01-20
WO2005005447A3 (fr) 2005-07-07
IL172513A0 (en) 2006-04-10
US20070021389A1 (en) 2007-01-25
ATE425170T1 (de) 2009-03-15
US7687636B2 (en) 2010-03-30
US20070021619A1 (en) 2007-01-25
US7589211B2 (en) 2009-09-15

Similar Documents

Publication Publication Date Title
US7582768B2 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
EP1930011B1 (fr) Forme cristalline de ibandronate de sodium
US7507829B2 (en) Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US8722722B2 (en) Raltegravir salts and crystalline forms thereof
EP2231612A1 (fr) Polymorphes de forme iii de tosylate de sorafénib, solvate de méthanol tosylate de sorafénib et solvate d'éthanol tosylate de sorafénib, et procédés de préparation associés
KR20080042131A (ko) 졸레드론산의 결정성 삼수화물
US20090076272A1 (en) Polymorphs of eszopiclone malate
WO2007074475A2 (fr) Nouvelles formes polymorphes de l'ibandronate
US20100113527A1 (en) Crystalline forms of dexlansoprazole
US20080262060A1 (en) Crystalline forms of Deferasirox
US20070259935A1 (en) Crystalline forms of letrozole and processes for making them
US20020107275A1 (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US6534674B2 (en) Crystalline disodium pamidronate hydrate and process for preparing it
WO2007036688A1 (fr) Sels et hydrates pharmaceutiquement acceptables de l’acide risédronique
US20230373998A1 (en) Solid state forms of lorecivivint
EP1795530A1 (fr) Procédé de préparation de sesquihydrate de sodium de pantoprazole connu
EP2109613A2 (fr) Polymorphes de malate d'eszopiclone

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARONHIME, JUDITH;LIFSHITZ-LIRON, REVITAL;REEL/FRAME:015372/0922;SIGNING DATES FROM 20040919 TO 20041004

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:015372/0897

Effective date: 20041019

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION